Quinton Oswald has been one of the leading thinkers in the medical industry for the past few decades. He was recently the CEO of Notal Vision, a company that is focused on telemedicine using the cloud and AI tools. Quinton Oswald Vero Beach believes that the fusion of these technologies is the key to the future of healthcare. He has worked tirelessly to push developments on this front until his retirement in December of 2018. Despite stepping down from his post and heading into a quieter life, his legacy lives on thanks to his various contributions to the field of medicine.
During his watch as the CEO of SARcode Bioscience, he led the company in its clinical development of the lifitegrast ophthalmic solution 5% also known as Xiidra. This is currently being used for treating dry eye disease. This condition is a result of a severe shortage in moisture and lubrication on the eye’s surface. Patients who experience this may complain about ongoing eye irritation, substantial inflammation, and surface scarring due to friction. It is actually a very common disease with prevalence levels ranging from 5% to 50% in different regions. Having a readily available treatment like Xiidra is a huge help for affected individuals.
Quinton Charles Oswald also served as a Vice President for Genentech. He was named as the Business Unit head of the company’s Tissue Growth and Repair Business. It was during this time that he supervised the commercial launch of Lucentis, otherwise known as ranibizumab. This is a drug developed for the treatment of wet age-related macular degeneration or wet AMD. This is one of the most frequent causes of vision loss for those who are 50 and older. Although it doesn’t cause total blindness, patients are likely to encounter problems with daily activities. Lucentis can be injected to slow down damage and maintain vision.
Mr. Oswald became part of the pharmaceutical giant Novartis in 2000. He initially served as the company’s Head of Global Sales before serving as its Head of Global Marketing and Sales Operations. He was also the leader of the North American Ophthalmology division for Novartis when they developed verteporfin, sold under the trade name Visudyne. This drug is administered intravenously minutes before laser treatment for wet AMD. It goes to the abnormal blood vessels and removes the blockage thanks to light stimulation. Verteporfin is also known to treat central serous retinopathy.
With three decades of Big Pharma experience under his belt, Mr. Oswald began to take his expertise to start-ups which were aiming to make major leaps in the medical industry. He described these start-ups as having been established by scientific founders who may not have had the knowledge or experience necessary to turn their ideas into mature products that were ready for commercial release. He used his considerable expertise in program development to guide these startups until they were good enough to be sold as a company or established enough to sell their own products.
As a corporate leader, his daily task was to use his influence to ensure that the senior team does what they are supposed to do. They agree on a strategy and execute it to the best of their abilities. All options need to be studied before making a final decision. If issues are encountered, then he coaches and counsels his team to keep them on track. Constant communication is important in ensuring that everyone is moving towards the same goal. Knowing the contributions of Quinton Oswald Florida has decided to honor him with a nomination for a prestigious medical award. There is no doubt that he will carry on inspiring others as Quinton Oswald Vero Beach Florida resident and tireless visionary.